Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes

Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by the progressive loss of dopaminergic (DA) neurons. Most PD cases are sporadic; however, rare familial forms have been identified. Autosomal recessive PD (ARPD) results from mutations in Parkin, PINK1, DJ-1, and A...

Full description

Saved in:
Bibliographic Details
Published in:Experimental neurology 2017-12, Vol.298 (Pt B), p.191-201
Main Authors: Scott, Laura, Dawson, Valina L., Dawson, Ted M.
Format: Article
Language:English
Subjects:
Animals
Autosomal recessive Parkinson's disease
Dopaminergic Neurons - pathology
Humans
Intracellular Signaling Peptides and Proteins - genetics
Intracellular Signaling Peptides and Proteins - metabolism
Mitochondria
Mitochondria - genetics
Mitochondria - metabolism
Mutation - genetics
Oxidative stress
Parkin
Parkinson Disease - genetics
Parkinson Disease - metabolism
Parkinsonian Disorders - genetics
Parkinsonian Disorders - pathology
PINK1
Protein degradation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by the progressive loss of dopaminergic (DA) neurons. Most PD cases are sporadic; however, rare familial forms have been identified. Autosomal recessive PD (ARPD) results from mutations in Parkin, PINK1, DJ-1, and ATP13A2, while rare, atypical juvenile ARPD result from mutations in FBXO7, DNAJC6, SYNJ1, and PLA2G6. Studying these genes and their function has revealed mitochondrial quality control, protein degradation processes, and oxidative stress responses as common pathways underlying PD pathogenesis. Understanding how aberrancy in these common processes leads to neurodegeneration has provided the field with numerous targets that may be therapeutically relevant to the development of disease-modifying treatments.
ISSN:0014-4886
1090-2430
DOI:10.1016/j.expneurol.2017.04.008